Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Shafer, Shulamith H (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220, C530S389100
Reexamination Certificate
active
08008446
ABSTRACT:
Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.
REFERENCES:
patent: 4690905 (1987-09-01), Diamond
patent: 4734433 (1988-03-01), Drabek
patent: 5703220 (1997-12-01), Yamada et al.
patent: 5908609 (1999-06-01), Lee et al.
patent: 6117975 (2000-09-01), Yamada et al.
patent: 6287763 (2001-09-01), Lee et al.
patent: 6537760 (2003-03-01), Bergmann et al.
patent: 6573070 (2003-06-01), MacNeil et al.
patent: 7034004 (2006-04-01), Haskell-Luevan et al.
patent: 7169777 (2007-01-01), Backer et al.
patent: 2004/0082779 (2004-04-01), Vos et al.
patent: 2007/0123453 (2007-05-01), Heiman et al.
patent: 0915706 (1997-12-01), None
patent: 1167386 (2002-02-01), None
patent: 9747316 (1997-12-01), None
patent: 9810068 (1998-03-01), None
patent: 9826294 (1998-06-01), None
patent: 0185930 (2001-11-01), None
patent: 03014742 (2003-02-01), None
Program for the Assessment of Clinical Cancer Tests, http://cancerdiagnosis.nci.nih.gov/assessment/progress/markerdev.htm, downloaded Feb. 3, 2010).
Hawkins 2004. Obesity Res. 12:107S-114S.
Gantz et al., “Molecular Cloning, Expression, and Gene Localization of a Fourth Melanocortin Receptor,” Journal of Biological Chemistry, 268(20), Jul. 15, 1993, pp. 15174-15179.
Cowley, “Hypothalamic Melanocortin Neurons Integrate Signals of Energy State,” European Journal of Pharmacology, 480, 2003, pp. 3-11.
Elies et al., “Immunochemical and Functional Characterization of an Agonist-Like Monoclonal Antibody Against the M2 Acetylcholine Receptor,” European Journal of Biochemistry, 251, 1998, pp. 659-666.
Peter et al., “Antibodies Against the Melanocortin-4 Receptor Act as Inverse Agonists In Vitro and In Vivo,” American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 292(6), 2007, pp. R2151-R2158.
Oi et al., “Lymphocyte Membrane IgG and Secreted IgG Are Structurally and Allotypically Distinct,” Journal of Experimental Medicine, 151, May 1980, pp. 1260-1274.
Mountjoy et al., “Localization of the Melanocortin-4 Receptor (MC4-R) in Neuroendocrine and Autonomic Control Circuits in the Brain,” Molecular Endocrinology, 8, 1994, pp. 1298-1308.
Peter et al., “Anti-Melanocortin-4 Receptor Autoantibodies in Obesity,” Journal of Clinical Endocrinology & Metabolism, 94 (3), 2009, pp. 793-800.
Biozentrum University of Basel Biennial Report 2006-2007, University of Basel, 2007 available at http://www.biozentrum.unibas.ch/report0607/biennial—0607—print.pdf.
Peter et al., “Pharmacologically Active Monoclonal Antibody Against the Human Melanocortin-4 Receptor as a Possible Treatment of Cachexia,” MipTec—The Leading European Event for Drug Discovery, Poster Session 1, Oct. 15, 2008, available at http://registration.akm.ch/einsicht—miptec.php? XNABSTRACT—ID=76605&XNSPRACHE—ID=2&XNKONGRESS—ID=80&XNMASKEN—ID=900.
Hofbauer et al., “Antibodies as Pharmacologic Tools for Studies on the Regulation of Energy Balance,” Nutrition, 24 (9), 2008, pp. 791-797.
Hofbauer Karl
Peter Jean-Christophe
Natzmer Joyce von
Pequignot & Myers LLC
Shafer Shulamith H
University of Basel
LandOfFree
Auto-antibodies against the melanocortin-4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Auto-antibodies against the melanocortin-4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Auto-antibodies against the melanocortin-4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727706